Please login to the form below

Not currently logged in
Email:
Password:

EU approval for AZ/BMS' first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

AstraZeneca BMS

AstraZeneca and Bristol-Myers Squibb are celebrating the approval of Forxiga in the EU, cementing another pillar of their wide-ranging diabetes collaboration into place.

Forxiga (dapagliflozin) becomes the first drug in the new sodium-glucose cotransporter 2 (SGLT2) inhibitor class to be approved for marketing anywhere in the world, and has been given a green light in the EU as a once-daily treatment for adults with type 2 diabetes.

SGLT2 inhibitors work independently of insulin to help remove excess glucose from the body, a mode of action not shared with any currently available treatments for type 2 diabetes. Rather than increasing the ability of insulin to tackle glucose, the drugs help the kidneys flush it from the body directly.

Commenting on the EU approval, John Wilding, head of the diabetes and endocrinology clinical research unit at University Hospital Aintree in the UK, said: "Many Europeans with type 2 diabetes are not reaching treatment goals, increasing their risk of developing complications, so there is a critical need for new treatments."

Forxiga adds to the classes of drugs already available for people with diabetes, and in addition to improving glucose control also confers additional benefits "such as weight loss and blood pressure lowering", he added.

EU approval should give AZ and BMS first-to-market advantage over other companies developing SGLT2 inhibitors, notably Johnson & Johnson's canagliflozin and Boehringer Ingelheim/Eli Lilly's empagliflozin. Canagliflozin was filed for approval in the US in June, while empagliflozin is scheduled for regulatory submissions during 2013.

However, Forxiga's route to market has not been so straightforward in the US, where earlier this year the FDA issued a complete response letter requesting additional data from ongoing studies to quell concerns of possible liver damage and a potential link with breast and bladder cancer.

Providing the FDA's concerns can be addressed, Forxiga could become a blockbuster for AZ and BMS, according to analysts.

Along with Forxiga, AZ and BMS have collaborated on the development of two other diabetes drugs - Onglyza (saxagliptin) and Kombiglyze (saxagliptin and metfomin) - and recently expanded their alliance after BMS acquired Amylin Pharmaceuticals in a $7bn deal.

15th November 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics